Ascendis Pharma A/S (BVMF:A1SN34)

Brazil flag Brazil · Delayed Price · Currency is BRL
76.24
+1.13 (1.50%)
At close: Jan 15, 2026
Market Cap72.29B +66.0%
Revenue (ttm)4.66B +98.0%
Net Income-1.47B
EPS-24.33
Shares Outn/a
PE Ration/a
Forward PE40.83
Dividendn/a
Ex-Dividend Daten/a
Volume1
Average Volume232
Open76.24
Previous Close75.11
Day's Range76.24 - 76.24
52-Week Range53.79 - 77.00
Beta0.43
RSI58.97
Earnings DateFeb 11, 2026

About Ascendis Pharma

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing o... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 1,189
Stock Exchange Brazil Stock Exchange
Ticker Symbol A1SN34
Full Company Profile

Financial Performance

In 2025, Ascendis Pharma's revenue was 720.13 million, an increase of 98.03% compared to the previous year's 363.64 million. Losses were -228.03 million, -39.69% less than in 2024.

Financial numbers in EUR Financial Statements